Share this post on:

Product Name :
Tucatinib

Search keywords :
Tucatinib

drugId :
null

Target Vo:
Receptor protein-tyrosine kinase erbB-2

Target Vo Short Name :
HER2

Moa_Name:
Receptor protein-tyrosine kinase erbB-2 antagonists

First Approval Country :
United States

First Approval Date Filter:
2020

Origin Company_Name :
Array Biopharma

Active Company_Name :
Almac Clinical Services

Active Indication_Name:
Breast Neoplasms

In Active Indication_Name:
Hepatic Insufficiency

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
Phase 3 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Lutikizumab Formula
PU.1 Rabbit mAb Data Sheet
mTOR Antibody (YA281): mTOR Antibody (YA281) is a non-conjugated and Rabbit origined monoclonal antibody about 289 kDa, targeting to mTOR. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.

Share this post on:

Author: Interleukin Related